Molecular Partners AG ADR
$ 4.23
-2.53%
26 Dec - close price
- Market Cap 158,198,000 USD
- Current Price $ 4.23
- High / Low $ 4.44 / 4.16
- Stock P/E N/A
- Book Value 3.23
- EPS -2.06
- Next Earning Report 2026-03-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.51 %
- 52 Week High 5.91
- 52 Week Low 3.36
About
Molecular Partners AG (MOLN) is an innovative clinical-stage biopharmaceutical company based in Schlieren, Switzerland, specializing in the development of advanced protein-based therapeutics aimed at oncology and viral infections. Leveraging its proprietary Darpin and Drug Conjugate technology platforms, the company strives to create targeted therapies that enhance treatment efficacy while minimizing side effects, addressing significant unmet medical needs. With a strong clinical pipeline and a dedication to scientific excellence, Molecular Partners is well-positioned to make impactful contributions to the biopharmaceutical landscape and improve patient outcomes globally.
Analyst Target Price
$10.85
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-25 | 2025-04-17 | 2025-03-06 | 2024-10-31 | 2024-08-27 | 2024-05-16 | 2024-03-14 | 2023-10-26 | 2023-08-28 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.33 | -0.6841 | -0.45 | -0.3 | -0.5629 | -0.46 | -0.6 | -0.6 | -0.3943 | -0.5417 | -0.4906 | -0.54 |
| Estimated EPS | -0.4795 | -0.4995 | -0.37 | -0.39 | -0.6288 | -1.26 | -1 | -0.97 | 0 | -0.87 | 0 | -0.9 |
| Surprise | 0.1495 | -0.1846 | -0.08 | 0.09 | 0.0659 | 0.8 | 0.4 | 0.37 | -0.3943 | 0.3283 | -0.4906 | 0.36 |
| Surprise Percentage | 31.1783% | -36.957% | -21.6216% | 23.0769% | 10.4803% | 63.4921% | 40% | 38.1443% | None% | 37.7356% | None% | 40% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3818 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MOLN
2025-12-18 07:10:18
Molecular Partners (MOLN) is set to present its latest developments and 2025 outlook at the 44th Annual J.P. Morgan Healthcare Conference, with CEO Patrick Amstutz speaking on January 15, 2026. The clinical-stage biotech company specializes in DARPin therapeutics and will cover corporate and clinical updates. This presentation follows a series of positive scientific and strategic updates that have generally led to positive market reactions for the company's stock.
2025-12-18 06:09:03
Molecular Partners AG, a clinical-stage biotech company specializing in DARPin therapeutics, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. CEO Patrick Amstutz will present the company's latest developments and 2025 outlook on January 15, 2025. A webcast of the presentation will be available on the company's website.
2025-12-12 10:08:29
Molecular Partners has established a Scientific Advisory Board (SAB) for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, a leading expert in nuclear medicine. The SAB aims to accelerate the development of targeted radiotherapeutics, guiding the company from early clinical validation to strategic development decisions. The board will provide critical input on candidate development, platform expansion, and cross-disciplinary innovation to bring improved treatment options to patients.
2025-12-12 09:08:51
Molecular Partners AG, a clinical-stage biotech company specializing in DARPin therapeutics, has established a Scientific Advisory Board (SAB) for its radiopharmaceuticals. Chaired by Prof. Ken Herrmann, M.D., a renowned nuclear medicine expert, the SAB also includes industry figures James Cook, Prof. Jason Lewis, Ph.D., and Prof. Michael Morris, M.D. This board aims to guide the strategic development and clinical validation of Molecular Partners' Radio-DARPin platform, which holds promise for delivering targeted radiotherapeutics for various cancers.
2025-12-11 12:09:25
Molecular Partners (MOLN) has established a Scientific Advisory Board (SAB) for its radiopharmaceutical program, led by Prof. Ken Herrmann, M.D. This SAB aims to accelerate the development of targeted radiotherapeutics, guiding the transition from early clinical validation to strategic development decisions. The company's lead candidates, MP0712 and MP0726, are Radio-DARPins targeting DLL3 and mesothelin, respectively, with MP0712 reportedly showing promising early human images and plans for Phase 1 initiation.
2025-12-11 07:00:00
Molecular Partners has established a Scientific Advisory Board (SAB) for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, M.D., a globally recognized nuclear medicine expert. The SAB, including other distinguished members, will provide critical guidance to transition the company's Radio-DARPin candidates, such as MP0712 and MP0726, from early clinical validation to strategic development and late-stage trials. This initiative aims to accelerate the development of targeted radiotherapies for cancer patients.
